Cardio Diagnostics Holdings is advancing cardiovascular disease detection by integrating AI with genetic and epigenetic biomarkers, aiming for more effective early risk identification and personalized interventions.
The company is developing a range of solutions that utilize artificial intelligence alongside genetic and epigenetic data to enhance the prevention, detection, and management of cardiovascular diseases. Their platform focuses on providing personalized insights through blood-based testing, which integrates these advanced biomarkers with AI analytics.
Currently, Cardio Diagnostics offers clinical tests such as Epi+Gen CHD and PrecisionCHD, which evaluate an individual's risk for coronary heart disease by analyzing a mix of genetic and epigenetic markers. Additionally, their offerings extend to population health and biopharma sectors with tools like HeartRisk and CardioInnovate360, aiming to manage cardiovascular health across various care stages.
This innovative approach has the potential to transform cardiovascular care from a reactive model to a proactive one, emphasizing early risk detection and tailored prevention strategies. By incorporating genetic insights, Cardio Diagnostics seeks to identify risks that conventional assessments might miss, thereby enhancing the overall effectiveness of cardiovascular disease management.
As the landscape of cardiovascular care evolves, Cardio Diagnostics' focus on integrating AI with genetic insights could significantly improve patient outcomes and streamline the path from early detection to personalized treatment.